23 results on '"Campone, Mario"'
Search Results
2. Functional pre-therapeutic evaluation by genome editing of variants of uncertain significance of essential tumor suppressor genes
- Author
-
Billaud, Amandine, Chevalier, Louise-Marie, Augereau, Paule, Frenel, Jean-Sebastien, Passot, Christophe, Campone, Mario, and Morel, Alain
- Published
- 2021
- Full Text
- View/download PDF
3. Molecular features of untreated breast cancer and initial metastatic event inform clinical decision-making and predict outcome: long-term results of ESOPE, a single-arm prospective multicenter study
- Author
-
Callens, Céline, Driouch, Keltouma, Boulai, Anaïs, Tariq, Zakia, Comte, Aurélie, Berger, Frédérique, Belin, Lisa, Bièche, Ivan, Servois, Vincent, Legoix, Patricia, Bernard, Virginie, Baulande, Sylvain, Chemlali, Walid, Bidard, François-Clément, Fourchotte, Virginie, Salomon, Anne Vincent-, Brain, Etienne, Lidereau, Rosette, Bachelot, Thomas, Saghatchian, Mahasti, Campone, Mario, Giacchetti, Sylvie, Zafrani, Brigitte Sigal, and Cottu, Paul
- Published
- 2021
- Full Text
- View/download PDF
4. The EPICURE study: a pilot prospective cohort study of heterogeneous and massive data integration in metastatic breast cancer patients
- Author
-
Colombié, Mathilde, Jézéquel, Pascal, Rubeaux, Mathieu, Frenel, Jean-Sébastien, Bigot, Frédéric, Seegers, Valérie, and Campone, Mario
- Published
- 2021
- Full Text
- View/download PDF
5. Forum theater staging of difficult encounters with patients to increase empathy in students: evaluation of efficacy at The University of Angers Medical School
- Author
-
Sevrain-Goideau, Marion, Gohier, Benedicte, Bellanger, William, Annweiler, Cedric, Campone, Mario, and Coutant, Regis
- Published
- 2020
- Full Text
- View/download PDF
6. A phase I/II study of epertinib plus trastuzumab with or without chemotherapy in patients with HER2-positive metastatic breast cancer
- Author
-
Macpherson, Iain R., Spiliopoulou, Pavlina, Rafii, Saeed, Saggese, Matilde, Baird, Richard D., Garcia-Corbacho, Javier, Italiano, Antoine, Bonneterre, Jacques, Campone, Mario, Cresti, Nicola, Posner, John, Takeda, Yousuke, Arimura, Akinori, and Spicer, James
- Published
- 2019
- Full Text
- View/download PDF
7. Androgen receptor and FOXA1 coexpression define a “luminal-AR” subtype of feline mammary carcinomas, spontaneous models of breast cancer
- Author
-
Dagher, Elie, Royer, Violette, Buchet, Paul, Abadie, Jérôme, Loussouarn, Delphine, Campone, Mario, and Nguyen, Frédérique
- Published
- 2019
- Full Text
- View/download PDF
8. Bcl-2 expression and prognostic significance in feline invasive mammary carcinomas: a retrospective observational study
- Author
-
Dagher, Elie, Abadie, Jérôme, Loussouarn, Delphine, Fanuel, Dominique, Campone, Mario, and Nguyen, Frédérique
- Published
- 2019
- Full Text
- View/download PDF
9. Identification of three subtypes of triple-negative breast cancer with potential therapeutic implications
- Author
-
Jézéquel, Pascal, Kerdraon, Olivier, Hondermarck, Hubert, Guérin-Charbonnel, Catherine, Lasla, Hamza, Gouraud, Wilfried, Canon, Jean-Luc, Gombos, Andrea, Dalenc, Florence, Delaloge, Suzette, Lemonnier, Jérôme, Loussouarn, Delphine, Verrièle, Véronique, and Campone, Mario
- Published
- 2019
- Full Text
- View/download PDF
10. Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2- breast cancer that had progressed during or after prior endocrine therapy.
- Author
-
Musolino, Antonino, Campone, Mario, Neven, Patrick, Denduluri, Neelima, Barrios, Carlos H., Cortes, Javier, Blackwell, Kimberly, Soliman, Hatem, Kahan, Zsuzsanna, Bonnefoi, Hervé, Squires, Matthew, Zhang, Yong, Deudon, Stephanie, Shi, Michael M., and André, Fabrice
- Subjects
FIBROBLAST growth factor receptors ,HORMONE receptors ,HORMONE therapy ,BREAST cancer ,PROGRESSION-free survival ,PROTEIN metabolism ,ANTINEOPLASTIC agents ,BREAST tumors ,CELL receptors ,COMPARATIVE studies ,ESTRADIOL ,HETEROCYCLIC compounds ,RESEARCH methodology ,MEDICAL cooperation ,METASTASIS ,QUINOLONE antibacterial agents ,REOPERATION ,RESEARCH ,RESEARCH funding ,SURVIVAL analysis (Biometry) ,TUMOR classification ,EVALUATION research ,RANDOMIZED controlled trials ,TREATMENT effectiveness ,POSTMENOPAUSE ,DISEASE progression - Abstract
Background: Overexpression of fibroblast growth factor receptor 1 (FGFR1), found in ≤8% of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer cases, is correlated with decreased overall survival and resistance to endocrine therapy (ET). Dovitinib, a potent FGFR inhibitor, has demonstrated antitumor activity in heavily pretreated patients with FGFR pathway-amplified breast cancer.Methods: In this randomized, placebo-controlled phase II trial, we evaluated whether the addition of dovitinib to fulvestrant would improve outcomes in postmenopausal patients with HR+, HER2- advanced breast cancer that had progressed during or after prior ET. Patients were stratified by FGF pathway amplification and presence of visceral disease, and they were randomized 1:1 to receive fulvestrant plus dovitinib or placebo. The primary endpoint was progression-free survival (PFS).Results: From 15 May 2012 to 26 November 2014, 97 patients from 36 centers were enrolled. The frequency of FGF pathway amplification was lower than anticipated, and the study was terminated early owing to slow accrual of patients with FGF pathway amplification. The median PFS (95% CI) was 5.5 (3.8-14.0) months vs 5.5 (3.5-10.7) months in the dovitinib vs placebo arms, respectively (HR, 0.68; did not meet predefined efficacy criteria). For the FGF pathway-amplified subgroup (n = 31), the median PFS (95% CI) was 10.9 (3.5-16.5) months vs 5.5 (3.5-16.4) months in the dovitinib vs placebo arms, respectively (HR, 0.64; met the predefined superiority criteria). Frequently reported adverse events in the dovitinib (diarrhea, nausea, vomiting, asthenia, and headache) and placebo (diarrhea, fatigue, nausea, and asthenia) arms were mostly low grade.Conclusions: The safety profile of dovitinib plus fulvestrant was consistent with the known safety profile of single-agent dovitinib. Dovitinib in combination with fulvestrant showed promising clinical activity in the FGF pathway-amplified subgroup. However, the data reported herein should be interpreted with caution, given that fewer PFS events occurred in the FGF pathway-amplified patients than was expected and that an effect of dovitinib regardless of FGR pathway amplification status cannot be excluded, because the population was smaller than expected.Trial Registration: ClinicalTrials.gov identifier: NCT01528345 . Registered 31 January 2012. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
11. Gene-expression signature functional annotation of breast cancer tumours in function of age.
- Author
-
Jézéquel, Pascal, Sharif, Zein, Lasla, Hamza, Gouraud, Wilfried, Guérin-Charbonnel, Catherine, Campion, Loïc, Chrétien, Stéphane, and Campone, Mario
- Subjects
GENE expression ,GENETICS of breast cancer ,BREAST cancer patients ,BREAST cancer prognosis ,IMMUNE response - Abstract
Background: Breast cancer biological characteristics change as age advances. Today, there is a lack of knowledge regarding age-specific molecular alterations that characterize breast tumours, notably in elderly patients. The vast majority of studies that aimed at exploring breast cancer in function of age are based on clinico-pathological data. Gene-expression signatures (GES), which in some ways capture biological information in a non-reductionist manner, represent powerful tools able to explore tumour heterogeneity. Methods: Twenty-five GES were used for functional annotation of breast tumours in function of age: five for molecular subtyping, seven for immune response, three for metabolism, seven for critical pathways in cancer and three for prognosis. Affymetrix® genomics datasets were exclusively used to avoid cross-platform normalization issues. Available corresponding clinico-pathological data were also retrieved and analysed. Results: Fifteen publicly available datasets were pooled for a total of 2378 breast cancer patients (whole cohort), out of whom 1413 were of Caucasian origin. Three age groups were defined: ≤ 40 years (AG1), > 40 to < 70 years (AG2) and ≥ 70 years (AG3). We confirmed that age influenced the incidence of molecular subtypes. We found a significant growing incidence of luminal B and a decreasing kinetics for basal-like in function of age. We showed that AG3 luminal B tumours were less aggressive than AG1 luminal B tumours based on different GES (iron metabolism, mitochondrial oxidative phosphorylation and reactive stroma), recurrence score prognostic GES and histological grade (SBR). Contrary to tumours of young patients, tumours of elderly patients concentrated favourable GES scores: high oestrogen receptor and mitochondrial oxidative phosphorylation, low proliferation, basal-like, glycolysis, chromosomal instability and iron metabolism, and low GES prognostic scores (van't Veer 70-GES, genomic grade index and recurrence score). Conclusions: Functional annotation of breast tumours by means of 25 GES demonstrated a decreasing aggressiveness of breast tumours in function of age. This strategy, which can be strengthened by increasing the number of representative GES to gain more insight into biological systems involved in this disease, provides a framework to develop rational therapeutic strategies in function of age. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
12. The dog as a naturally-occurring model for insulin-like growth factor type 1 receptor-overexpressing breast cancer: an observational cohort study.
- Author
-
Jaillardon, Laetitia, Abadie, Jérome, Godard, Tiffanie, Campone, Mario, Loussouarn, Delphine, Siliart, Brigitte, and Nguyen, Frédérique
- Subjects
TRIPLE-negative breast cancer ,INSULIN-like growth factor receptors ,CANCER in dogs ,MAMMARY gland cancer ,CANCER invasiveness ,EPIDERMAL growth factor receptors ,ANIMAL experimentation ,BIOLOGICAL models ,BREAST tumors ,DOGS ,GENE expression ,IMMUNOPHENOTYPING ,LONGITUDINAL method ,PROGNOSIS ,TUMOR grading - Abstract
Background: Dogs spontaneously develop invasive mammary carcinoma with a high prevalence of the triple-negative (TN) subtype (lack of ER-Estrogen Receptor and PR-Progesterone Receptor expression, lack of HER2-Human Epidermal Growth Factor Receptor 2 overexpression), making this animal model relevant for investigating new therapeutic pathways. Insulin-like growth factor Type-1 receptor (IGF1R) is frequently overexpressed in primary human breast cancers, with a growing role in the TN phenotype. The purpose of this study was to investigate the Dog as a candidate model for IGF1R-overexpressing mammary carcinoma.Methods: 150 bitches with canine mammary carcinoma (CMC) and a known 2-year follow-up were retrospectively included. IGF1R expression was assessed by immunohistochemistry (IHC) using a similar scoring system as for HER2 in breast cancer. The prognostic value of the IGF1R expression was assessed in terms of overall and specific survival as well as disease-free interval (DFI).Results: 47 CMC (31 %) were classified as luminal and 103 (69 %) as triple-negative (TN-CMC). 41 % of CMC overexpressed IGF1R (IHC score 3+) of which 76 % were TN-CMC and 62 % grade III. IGF1R overexpression was associated with aggressive features including lymphovascular invasion, histological grade III, low ER expression and the TN phenotype. Univariate and multivariate analyses revealed that IGF1R overexpression was associated with shorter overall and specific survivals and shorter DFI in TN-CMC.Conclusions: IGF1R overexpression is common and related to a poor outcome in canine invasive mammary carcinoma, particularly in the triple negative subtype, as in human breast cancer. Preclinical studies using the Dog as a spontaneous animal model could be considered to investigate new therapies targeting IGF1R in triple-negative breast cancer. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
13. Gene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune response.
- Author
-
Jézéquel, Pascal, Loussouarn, Delphine, Guérin-Charbonnel, Catherine, Campion, Loïc, Vanier, Antoine, Gouraud, Wilfried, Lasla, Hamza, Guette, Catherine, Valo, Isabelle, Verrièle, Véronique, and Campone, Mario
- Subjects
GENE expression in viruses ,TRIPLE-negative breast cancer ,IMMUNE response ,BREAST cancer patients ,IMMUNOHISTOCHEMISTRY ,FUZZY clustering technique - Abstract
Introduction: Triple-negative breast cancers need to be refined in order to identify therapeutic subgroups of patients Methods: We conducted an unsupervised analysis of microarray gene-expression profiles of 107 triple-negative breast cancer patients and undertook robust functional annotation of the molecular entities found by means of numerous approaches including immunohistochemistry and gene-expression signatures. A triple-negative external cohort (n = 87) was used for validation. Results: Fuzzy clustering separated triple-negative tumours into three clusters: C1 (22.4%), C2 (44.9%) and C3 (32.7%). C1 patients were older (mean = 64.6 years) than C2 (mean = 56.8 years; P = 0.03) and C3 patients (mean = 51.9 years; P = 0.0004). Histological grade and Nottingham prognostic index were higher in C2 and C3 than in C1 (P < 0.0001 for both comparisons). Significant event-free survival (P = 0.03) was found according to cluster membership: patients belonging to C3 had a better outcome than patients in C1 (P = 0.01) and C2 (P = 0.02). Event-free survival analysis results were confirmed when our cohort was pooled with the external cohort (n = 194; P = 0.01). Functional annotation showed that 22% of triple-negative patients were not basal-like (C1). C1 was enriched in luminal subtypes and positive androgen receptor (luminal androgen receptor). C2 could be considered as an almost pure basal-like cluster. C3, enriched in basal-like subtypes but to a lesser extent, included 26% of claudin-low subtypes. Dissection of immune response showed that high immune response and low M2-like macrophages were a hallmark of C3, and that these patients had a better event-free survival than C2 patients, characterized by low immune response and high M2-like macrophages: P = 0.02 for our cohort, and P = 0.03 for pooled cohorts. Conclusions: We identified three subtypes of triple-negative patients: luminal androgen receptor (22%), basal-like with low immune response and high M2-like macrophages (45%), and basal-enriched with high immune response and low M2-like macrophages (33%). We noted out that macrophages and other immune effectors offer a variety of therapeutic targets in breast cancer, and particularly in triple-negative basal-like tumours. Furthermore, we showed that CK5 antibody was better suited than CK5/6 antibody to subtype triple-negative patients. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
14. Phase I dose-finding study of cabazitaxel administered weekly in patients with advanced solid tumours.
- Author
-
Fumoleau, Pierre, Trigo, Jose Manuel, Isambert, Nicolas, Sémiond, Dorothée, Gupta, Sunil, and Campone, Mario
- Subjects
TUMOR diagnosis ,ANTINEOPLASTIC agents ,CLINICAL trials ,COMBINED modality therapy ,COMPARATIVE studies ,DRUG dosage ,DRUG toxicity ,HYDROCARBONS ,RESEARCH methodology ,MEDICAL cooperation ,RESEARCH ,TUMORS ,TUMOR classification ,EVALUATION research ,TREATMENT effectiveness ,PHARMACODYNAMICS ,THERAPEUTICS - Abstract
Background: Cabazitaxel is approved in patients with metastatic hormone-refractory prostate cancer previously treated with a docetaxel-containing regimen. This study evaluated a weekly cabazitaxel dosing regimen. Primary objectives were to report dose-limiting toxicities (DLTs) and to determine the maximum tolerated dose (MTD). Efficacy, safety and pharmacokinetics were secondary objectives.Methods: Cabazitaxel was administered weekly (1-hour intravenous infusion at 1.5-12 mg/m² doses) for the first 4 weeks of a 5-week cycle in patients with solid tumours. Monitoring of DLTs was used to determine the MTD and the recommended weekly dose.Results: Thirty-one patients were enrolled. Two of six patients experienced DLTs at 12 mg/m², which was declared the MTD. Gastrointestinal disorders were the most common adverse event. Eight patients developed neutropenia (three ≥ Grade 3); one occurrence of febrile neutropenia was reported. There were two partial responses (in breast cancer) and 13 patients had stable disease (median duration of 3.3 months). Increases in C(max) and AUC(0-t) were dose proportional for the 6-12 mg/m² doses.Conclusion: The MTD of weekly cabazitaxel was 12 mg/m² and the recommended weekly dose was 10 mg/m². The observed safety profile and antitumour activity of cabazitaxel were consistent with those observed with other taxanes in similar dosing regimens.Trial Registration: The study was registered with ClinicalTrials.gov as NCT01755390. [ABSTRACT FROM AUTHOR]- Published
- 2013
- Full Text
- View/download PDF
15. γ-Secretase inhibition promotes cell death, Noxa upregulation, and sensitization to BH3 mimetic ABT-737 in human breast cancer cells.
- Author
-
Séveno, Céline, Loussouarn, Delphine, Bréchet, Sophie, Campone, Mario, Juin, Philippe, and Barillé-Nion, Sophie
- Subjects
CELL death ,BREAST cancer ,CELL lines ,HOMOLOGY (Biology) ,APOPTOSIS - Abstract
Introduction: Inappropriate Notch signaling, downstream of γ-secretase activity, is understood to have tumorpromoting function and to be associated with poor outcome in cancer, of the breast in particular. The molecular basis of antitumoral effects of its inhibitors, however, remains poorly characterized. Moreover, the effects of their combination with the pro-apoptotic pharmacologic inhibitor of Bcl-2/Bcl-xL, ABT-737, have never been evaluated. In this study, we thus specifically addressed the biologic consequences of targeting g-γsecretase and Bcl-2/Bcl-xL, alone or simultaneously, in breast cancer cell lines as well as in a novel human breast cancer ex vivo assay. Methods: By using in vitro 2D or 3D cultures of breast cancer cells plus a novel preclinical short-term ex vivo assay that correctly maintains human mammary tissue integrity and preserves tumor microenvironment, we tested the effects of the pharmacologic g-γsecretase inhibitor GSIXII used as a single agent or in combination with ABT-737. Results: We show herein that the g-γsecretase inhibitor, GSIXII, efficiently induces apoptosis in breast cancer cell lines by a process that relies on the induction of Noxa, a pro-apoptotic Bcl2-homology 3 domain (BH3)-only protein of the Bcl-2 family that functions as an inhibitor of antiapoptotic Mcl1. GSIXII also targets mammary cancer stem-like cells because it dramatically prevents in vitro mammosphere formation. Moreover, combining GSIXII treatment with ABT-737, a BH3- mimetic inhibitor of additional antiapoptotic proteins, such as Bcl-2 and Bcl-xL, leads to both a synergistic apoptotic response in breast cancer cells and to an inhibitory effect on mammosphere formation. These effects are also found when a Notch transcriptional inhibitor, SAHM1, is used. Finally, we evaluated individual human tumor responses to g-γsecretase inhibition alone or in combination with ABT-737 in ex vivo assays. Analysis of a series of 30 consecutive tumors indicated that a majority of tumors are sensitive to apoptosis induction by GSIXII and that association of GSIXII with ABT-737 leads to an enhanced induction of apoptosis in tumor cells. Conclusions: We thus provide evidence that g-γsecretase, and downstream Notch signaling, are relevant targets in breast cancer. GSIXII, used as single agent or in combination with clinically relevant BH3-mimetics, is a promising innovative proapoptotic strategy to treat mammary tumors. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
16. miR-720 is a downstream target of an ADAM8-induced ERK signaling cascade that promotes the migratory and invasive phenotype of triple-negative breast cancer cells.
- Author
-
Das, Sonia G., Romagnoli, Mathilde, Mineva, Nora D., Barillé-Nion, Sophie, Jézéquel, Pascal, Campone, Mario, and Sonenshein, Gail E.
- Subjects
CANCER cells ,GENETICS of breast cancer ,PHENOTYPES ,METASTASIS ,METALLOPROTEINASES ,ANIMAL experimentation ,ANIMALS ,BREAST tumors ,CANCER invasiveness ,CELL lines ,CELL physiology ,CELL motility ,CELLULAR signal transduction ,GENES ,GENETIC techniques ,GLYCOPROTEINS ,MEMBRANE proteins ,MICE ,RESEARCH funding ,RNA - Abstract
Background: ADAM8 (a disintegrin and metalloproteinase 8) protein promotes the invasive and metastatic phenotype of triple-negative breast cancer (TNBC) cells. High ADAM8 expression in breast cancer patients is an independent predictor of poor prognosis. Here, we investigated whether ADAM8 regulates specific miRNAs, their roles in aggressive phenotype, and potential use as biomarkers of disease.Methods: Microarray analysis was performed on RNA from MDA-MB-231 cells after transient ADAM8 knockdown using TaqMan miRNA cards. Changes in miRNA levels were confirmed using two ADAM8 siRNAs in TNBC cell lines. Kinase inhibitors, β1-integrin antagonist antibody, and different forms of ADAM8 were employed to elucidate the signaling pathway required for miR-720 expression. miR-720 levels were modulated using a specific antagomiR or a mimic, and effects on aggressive phenotype of TNBC cells were determined using Boyden chamber and 3D-Matrigel outgrowth assays. Plasma was isolated from mice before and after implantation of MDA-MB-231 cells and analyzed for miR-720 levels. Serum samples of TNBC patients were evaluated for their ADAM8 and miR-720 levels.Results: We identified 68 miRNAs differentially regulated upon ADAM8 knockdown, including decreased levels of secreted miR-720. Ectopic overexpression of wild-type ADAM8 or forms that lack metalloproteinase activity similarly induced miR-720 levels. The disintegrin and cysteine-rich domains of ADAM8 were shown to induce miR-720 via activation of a β1-integrin to ERK signaling cascade. Knockdown of miR-720 led to a significant decrease in migratory and invasive abilities of TNBC cells. Conversely, miR-720 overexpression rescued these properties. A profound increase in plasma levels of miR-720 was detected 7 days after TNBC cell inoculation into mouse mammary fat pads when tumors were barely palpable. Concordantly, miR-720 levels were found to be significantly higher in serum samples of TNBC patients with high ADAM8 expression.Conclusions: We have shown for the first time that miR-720 is induced by ADAM8 signaling via ERK and plays an essential role in promoting the aggressive phenotype of TNBCs. miR-720 is elevated in serum of patients with ADAM8-high TNBC and, in a group with other miRNAs downstream of ADAM8, holds promise as a biomarker for early detection of or treatment response of ADAM8-positive TNBCs. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
17. Assessment of circulating tumor cells and serum markers for progression-free survival prediction in metastatic breast cancer: a prospective observational study.
- Author
-
Bidard, François-Clément, Hajage, David, Bachelot, Thomas, Delaloge, Suzette, Brain, Etienne, Campone, Mario, Cottu, Paul, Beuzeboc, Philippe, Rolland, Emilie, Mathiot, Claire, and Pierga, Jean-Yves
- Subjects
DIAGNOSTIC use of tumor markers ,BIOMARKERS ,BREAST cancer diagnosis ,BREAST cancer patients ,CANCER chemotherapy - Abstract
Introduction: Circulating tumor cells (CTC) have been recently proposed as a new dynamic blood marker whose positivity at baseline is a prognostic factor and whose changes under treatment are correlated with progression-free survival (PFS) in metastatic breast cancer patients. However, serum marker levels are also used for the same purpose, and no clear comparison has been reported to date.Methods: The IC 2006-04 enrolled prospectively 267 metastatic breast cancer patients treated by first line chemotherapy and confirmed that CTC levels are an independent prognostic factor for PFS and overall survival (OS). A secondary pre-planned endpoint was to compare prospectively the positivity rates and the value of CTC (CellSearch®), of serum tumor markers (carcinoembryonic antigen (CEA), cancer antigen 15.3 (CA 15-3), CYFRA 21-1), and of serum non-tumor markers (lactate deshydrogenase (LDH), alkaline phosphatase (ALP)) at baseline and under treatment for PFS prediction, independently from the other known prognostic factors, using univariate analyses and concordance indexes.Results: A total of 90% of the patients had at least one elevated blood marker. Blood markers were correlated with poor performance status, high number of metastatic sites and with each other. In particular, CYFRA 21-1, a marker usually used in lung cancer, was elevated in 65% of patients. A total of 86% of patients had either CA 15-3 and/or CYFRA 21-1 elevated at baseline. Each serum marker was associated, when elevated at baseline, with a significantly shorter PFS. Serum marker changes during treatment, assessed either between baseline and week 3 or between baseline and weeks 6 to 9, were significantly associated with PFS, as reported for CTC. Concordance indexes comparison showed no clear superiority of any of the serum marker or CTC for PFS prediction.Conclusions: For the purpose of PFS prediction by measuring blood marker changes during treatment, currently available blood-derived markers (CTC and serum markers) had globally similar performances. Besides CEA and CA 15-3, CYFRA 21-1 is commonly elevated in metastatic breast cancer and has a strong prognostic value. [ABSTRACT FROM AUTHOR]- Published
- 2012
- Full Text
- View/download PDF
18. Cytosine methylation of mature microRNAs inhibits their functions and is associated with poor prognosis in glioblastoma multiforme.
- Author
-
Cheray, Mathilde, Etcheverry, Amandine, Jacques, Camille, Pacaud, Romain, Bougras-Cartron, Gwenola, Aubry, Marc, Denoual, Florent, Peterlongo, Pierre, Nadaradjane, Arulraj, Briand, Joséphine, Akcha, Farida, Heymann, Dominique, Vallette, François M., Mosser, Jean, Ory, Benjamin, and Cartron, Pierre-François
- Subjects
GLIOBLASTOMA multiforme ,CYTOSINE ,METHYLATION ,GENE transfection ,METHYL groups - Abstract
Background: Literature reports that mature microRNA (miRNA) can be methylated at adenosine, guanosine and cytosine. However, the molecular mechanisms involved in cytosine methylation of miRNAs have not yet been fully elucidated. Here we investigated the biological role and underlying mechanism of cytosine methylation in miRNAs in glioblastoma multiforme (GBM). Methods: RNA immunoprecipitation with the anti-5methylcytosine (5mC) antibody followed by Array, ELISA, dot blot, incorporation of a radio-labelled methyl group in miRNA, and miRNA bisulfite sequencing were perfomred to detect the cytosine methylation in mature miRNA. Cross-Linking immunoprecipiation qPCR, transfection with methylation/unmethylated mimic miRNA, luciferase promoter reporter plasmid, Biotin-tagged 3'UTR/mRNA or miRNA experiments and in vivo assays were used to investigate the role of methylated miRNAs. Finally, the prognostic value of methylated miRNAs was analyzed in a cohorte of GBM pateints. Results: Our study reveals that a significant fraction of miRNAs contains 5mC. Cellular experiments show that DNMT3A/AGO4 methylated miRNAs at cytosine residues inhibit the formation of miRNA/mRNA duplex and leading to the loss of their repressive function towards gene expression. In vivo experiments show that cytosine-methylation of miRNA abolishes the tumor suppressor function of miRNA-181a-5p miRNA for example. Our study also reveals that cytosine-methylation of miRNA-181a-5p results is associated a poor prognosis in GBM patients. Conclusion: Together, our results indicate that the DNMT3A/AGO4-mediated cytosine methylation of miRNA negatively. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
19. Role of delayed salvage bevacizumab at symptomatic progression of chemorefractory glioblastoma.
- Author
-
Cuncannon, Moire, Wong, Matthew, Jayamanne, Dasantha, Guo, Linxin, Cove, Nicola, Wheeler, Helen, and Back, Michael
- Subjects
BEVACIZUMAB ,DISEASE relapse ,GLIOBLASTOMA multiforme ,SALVAGE therapy - Abstract
Background: Assess benefit of salvage bevacizumab (BEV) at time of symptomatic progression in patients with refractory glioblastoma (GBM).Methods: Patients managed with adjuvant long course chemo-radiation therapy for GBM were entered into a prospective database. At chemorefractory symptomatic progression, patients were offered BEV or best supportive care. Re-irradiation (ReRT) was used with BEV in selected patients. BEV continued indefinitely until deterioration limited hospital based infusion. The primary endpoint was median survival calculated from date of decision for BEV to proceed (BEVstart), or decision to decline BEV (BEVreject).Results: Fifty-five patients were managed of which 48 patients have relapsed disease. The median survival post relapse was 6 months (95%CI: 4.6-7.4). At relapse, 28 patients received BEV with only 14% delivered at first relapse. The median number of BEV cycles was 8 (range 1-25). ReRT was subsequently used in 16 (33%) relapsed patients. BEV treated patients were associated with improved median survival post relapse with 9 months vs 3 months (p < 0.01). The median survival from BEV related decision-making at symptomatic refractory progression to death was 4 months (95%CI: 2.0-6.0). BEVstart was associated with improved survival from this date with median survival of 6 months vs 1 month with BEVreject (p < 0.01). Median survival with ReRT from this date was 8 months vs 3 months without ReRT (p = 0.01). In the BEV patients at eventual progression, death occurred at a median of 30 days post BEV cessation.Conclusion: In this clinic managing selected patients with chemorefractory progressive glioblastoma, delayed salvage bevacizumab, often in combination with re-irradiation, may provide an increase in survival duration compared with best supportive care. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
20. Detection of PIK3/AKT pathway in Moroccan population with triple negative breast cancer.
- Author
-
Jouali, Farah, Marchoudi, Nabila, Talbi, Salwa, Bilal, Basma, El Khasmi, Mohamed, Rhaissi, Houria, and Fekkak, Jamal
- Subjects
BREAST cancer ,PROTEIN kinase B ,CANCER ,GENETIC mutation ,PHOSPHOINOSITIDES ,PHOSPHOLIPIDS - Abstract
Background: Triple Negative Breast Cancer (TNBC) is an aggressive form of breast cancer, that represents 10-20% of all breast carcinomas and characterized by the lack of a specific cell surface marker compared to other breast cancer subtypes. Due to the absence of molecular markers for TNBC his treatment options remains limited, without proven targeted therapies, which emphasize the need for discovering molecular markers that could be targeted for patient treatment, An important number of TNBC cases harbor aberrations in the phosphoinositide 3-kinase (PI3K) pathway, leading to constitutive activation of the downstream signaling pathway. Among mechanisms of PI3K enhancement, PIK3CA mutations are most frequently (~ 30%) observed, along with protein loss of PTEN and AKT activation by phosphorylation (pAkt). Therefore, we propose to analyze clinocopathologic and molecular characteristics of PI3K/AKT/PTEN pathway in Moroccan triple negative breast cancer patients.Methods: We conducted a retrospective study of 39 patients diagnosed with triple negative breast cancer between early 2013 and 2016. In this study, we used the Ion Personal Genome Machine (PGM) and Ion Torrent Ampliseq Cancer panel to sequence hotspot regions from PIK3CA, AKT and PTEN genes to identify genetic mutations in 39 samples of TNBC subtype from Moroccan patients and to correlate the results with clinical-pathologic data.Results: All patients were female with a median age of 46 years from (34-65). Most patients have had invasive ductal carcinoma (84.6%) and 69.2% of them were grade III SBR. Among the 39, 9 were right sided tumor patients and the remaining 30 were left-sided. Mutational analysis of PIK3CA gene was achieved in all TNBC patients. PIK3CA hotspot mutations were detected in 5/39 of TNBC (13%), in detail, among these 5 TNBC patients, one harbored mutation in exons 9 and four in exon 20.Conclusion: The PI3KCA gene is highly activated and plays a crucial role in the pathogenesis of TNBC more, therefore, may be a potential therapeutic target to improve outcomes in patients. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
21. HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates.
- Author
-
Ocaña, Alberto, Amir, Eitan, and Pandiella, Atanasio
- Subjects
ANTIBODY-drug conjugates ,HETEROGENEITY ,BREAST cancer - Abstract
Background: There has been substantial interest in HER2 intratumoral heterogeneity as an explanation for the development of resistance to anti-HER2 therapies in breast cancer, particularly to trastuzumab emtansine (T-DM1).Methods: Through a literature-based approach, we discuss mechanisms of resistance to HER2-targeting antibody-drug conjugates (ADCs) in breast cancer.Results: We describe results from clinical studies reporting the effect of anti-HER2 strategies particularly ADCs and their mechanistic effect. We review biological findings underlying HER2 heterogeneity and its implication in the development of novel anti-HER2 drugs including new ADCs in clinical development like trastuzumab deruxtecan (DS-8201).Conclusions: We suggest potential mechanisms to optimize these compounds and their future clinical implementation. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
22. Phase I clinical trial of the combination of eribulin and everolimus in patients with metastatic triple-negative breast cancer.
- Author
-
Lee, Jin Sun, Yost, Susan E., Blanchard, Suzette, Schmolze, Daniel, Yin, Hongwei Holly, Pillai, Raju, Robinson, Kim, Tang, Aileen, Martinez, Norma, Portnow, Jana, Wen, Wei, Yim, John H., Brauer, Heather Ann, Ren, Yuqi, Luu, Thehang, Mortimer, Joanne, and Yuan, Yuan
- Subjects
TRIPLE-negative breast cancer ,METASTATIC breast cancer ,EVEROLIMUS ,CLINICAL trials ,ERIBULIN - Abstract
Background: Alteration of the PI3K/AKT/mTOR pathway is a common genomic abnormality detected in triple-negative breast cancer (TNBC). Everolimus acts synergistically with eribulin in TNBC cell lines and xenograft models. This phase I trial was designed to test the safety and tolerability of combining eribulin and everolimus in patients with metastatic TNBC.Methods: The primary objective of this study was to evaluate the safety and toxicities of the combination. Patients with metastatic TNBC who had up to four lines of prior chemotherapies were enrolled. The combination of eribulin and everolimus was tested using three dosing levels: A1 (everolimus 5 mg daily; eribulin 1.4 mg/m2 days 1 and 8 every 3 weeks), A2 (everolimus 7.5 mg daily; eribulin 1.4 mg/m2, days 1 and 8 every 3 weeks), and B1 (everolimus 5 mg daily; eribulin 1.1 mg/m2 days 1 and 8 every 3 weeks).Results: Twenty-seven patients with median age 55 years were enrolled. Among 8 evaluable patients who received dose level A1, 4 had dose-limiting toxicities (DLTs). Among 3 evaluable patients treated with dose level A2, 2 had DLTs. Among 12 evaluable patients who received dose level B1, 4 had DLTs. The DLTs were neutropenia, stomatitis, and hyperglycemia. Over the study period, 59% had a ≥ grade 3 toxicity, 44% had ≥ grade 3 hematologic toxicities, and 22% had grade 4 hematologic toxicities. The most common hematological toxicities were neutropenia, leukopenia, and lymphopenia. Thirty-three percent had grade 3 non-hematologic toxicities. The most common non-hematological toxicities were stomatitis, hyperglycemia, and fatigue. The median number of cycles completed was 4 (range 0-8). Among 25 eligible patients, 9 patients (36%) achieved the best response as partial response, 9 (36%) had stable disease, and 7 (28%) had progression. The median time to progression was 2.6 months (95% CI [2.1, 4.0]), and median overall survival (OS) was 8.3 months (95% CI [5.5, undefined]).Conclusion: Eribulin 1.1 mg/m2 days 1 and 8 every 3 weeks with everolimus 5 mg daily was defined as the highest dose with acceptable toxicity (RP2D). The combination is safe, and efficacy is modest. A post hoc analysis showed that participants that used dexamethasone mouthwash stayed on treatment for one additional cycle.Trial Registration: ClinicalTrials.gov, NCT02120469. Registered 18 April 2014. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
23. Meta-analysis of pain and function placebo responses in pharmacological osteoarthritis trials.
- Author
-
Huang, ZeYu, Chen, Jing, Hu, Qin Sheng, Huang, Qiang, Ma, Jun, Pei, Fu Xing, Shen, Bin, and Kraus, Virginia Byers
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.